Product Name

CD70 ADC

Description

CD70 is an antigen that has limited expression on normal cells but is found to be overexpressed in a broad range of hematologic tumors and also on solid tumors, including glioblastoma, renal and nasopharyngeal cancers. We have developed site-specific ADCs that use our proprietary drug payloads which we believe will be able to achieve enhanced efficacy and decreased overall toxicity (have a wider Therapeutic Index (TI)) compared with conventional ADCs. Thus, we expect the ADCs to show increased potency in cancer patients while decreasing the toxicity that is usually seen in other ADCs due to the heterogeneity of the random conjugation approach used to generate these molecules. We are developing the anti-CD70 ADC for treatment of renal cancer and nasopharyngeal cancers.


Download
Fact Sheet

Download
Data Sheet

Download
Video